Author/Authors :
André J. Scheen، نويسنده , , Nick Finer، نويسنده , , Priscilla Hollander، نويسنده , , Michael D Jensen، نويسنده , , Luc F Van Gaal and for the STORM Study Group، نويسنده ,
Abstract :
Background
Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy an
